Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b /2a adaptive trial of BOLD-100 in gastric, pancreatic, colorectal and bile duct (cholangiocarinoma) cancers

Next Previous
Trial Profile

Phase 1b /2a adaptive trial of BOLD-100 in gastric, pancreatic, colorectal and bile duct (cholangiocarinoma) cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BOLD 100 (Primary)
  • Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bold Therapeutics

Most Recent Events

  • 24 Jun 2022 According to a Bold Therapeutics media release, the company is actively enrolling patients at 13 clinical sites.
  • 24 Jun 2022 Status changed from planning to recruiting, according to a Bold Therapeutics media release.
  • 13 Jan 2022 According to a Bold Therapeutics media release, this study will be conducted at six sites in Canada, two sites in the U.S., and now five sites in South Korea.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top